PMID- 30105309
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2405-5808 (Electronic)
IS  - 2405-5808 (Linking)
VI  - 15
DP  - 2018 Sep
TI  - Podocalyxin is crucial for the growth of oral squamous cell carcinoma cell line 
      HSC-2.
PG  - 93-96
LID - 10.1016/j.bbrep.2018.07.008 [doi]
AB  - Oral cancers constitute approximately 2% of all cancers, with the most common 
      histological type being oral squamous cell carcinoma (OSCC), representing 90% of 
      oral cancers. Although diagnostic technologies and therapeutic techniques have 
      progressed, the survival rate of patients with OSCC is still 60%, whereas the 
      incidence rate has increased. Podocalyxin (PODXL) is a highly glycosylated type I 
      transmembrane protein that is detected in normal tissues such as heart, breast, 
      and pancreas as well as in many cancers, including lung, renal, breast, 
      colorectal, and oral cancers. This glycoprotein is associated with the 
      progression, metastasis, and poor outcomes of oral cancers. PODXL overexpression 
      was strongly detected using our previously established anti-PODXL monoclonal 
      antibody (mAb), PcMab-47, and its mouse IgG(2a)-type, 47-mG(2a). In previous 
      studies, we also generated PODXL-knock out (PODXL-KO) cell lines using SAS OSCC 
      cell lines, in order to investigate the function of PODXL in the proliferation of 
      oral cancer cells. The growth of SAS/PODXL-KO cell lines was observed to be lower 
      than that of parental SAS cells. For this study, PODXL-KO OSCC cell lines were 
      generated using HSC-2 cells, and the role of PODXL in the growth of OSCC cell 
      lines in vitro was assessed. Decreased growth was observed for HSC-2/PODXL-KO 
      cells compared with HSC-2 parental cells. The influence of PODXL on tumor growth 
      of OSCC was also investigated in vivo, and both the tumor volume and the tumor 
      weight were observed to be significantly lower for HSC-2/PODXL-KO than that for 
      HSC-2 parental cells. These results, taken together, indicate that PODXL plays an 
      important role in tumor growth, both in vitro and in vivo.
FAU - Itai, Shunsuke
AU  - Itai S
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
AD  - Department of Oral and Maxillofacial Surgery, Graduate School of Medical and 
      Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, 
      Tokyo 113-8510, Japan.
FAU - Yamada, Shinji
AU  - Yamada S
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
FAU - Kaneko, Mika K
AU  - Kaneko MK
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
FAU - Sano, Masato
AU  - Sano M
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
FAU - Nakamura, Takuro
AU  - Nakamura T
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
FAU - Yanaka, Miyuki
AU  - Yanaka M
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
FAU - Handa, Saori
AU  - Handa S
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
FAU - Hisamatsu, Kayo
AU  - Hisamatsu K
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
FAU - Nakamura, Yoshimi
AU  - Nakamura Y
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
FAU - Furusawa, Yoshikazu
AU  - Furusawa Y
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
AD  - New Industry Creation Hatchery Center, Tohoku University, 2-1, Seiryo-machi, 
      Aoba-ku, Sendai, Miyagi 980-8575, Japan.
AD  - ZENOAQ RESOURCE CO., LTD., 1-1 Tairanoue, Sasagawa, Asaka-machi, Koriyama, 
      Fukushima 963-0196, Japan.
FAU - Fukui, Masato
AU  - Fukui M
AD  - ZENOAQ RESOURCE CO., LTD., 1-1 Tairanoue, Sasagawa, Asaka-machi, Koriyama, 
      Fukushima 963-0196, Japan.
FAU - Ohishi, Tomokazu
AU  - Ohishi T
AD  - Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research 
      Foundation, 18-24 Miyamoto, Numazu, Shizuoka 410-0301, Japan.
FAU - Kawada, Manabu
AU  - Kawada M
AD  - Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research 
      Foundation, 18-24 Miyamoto, Numazu, Shizuoka 410-0301, Japan.
FAU - Harada, Hiroyuki
AU  - Harada H
AD  - Department of Oral and Maxillofacial Surgery, Graduate School of Medical and 
      Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, 
      Tokyo 113-8510, Japan.
FAU - Kato, Yukinari
AU  - Kato Y
AD  - Department of Antibody Drug Development, Tohoku University Graduate School of 
      Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.
AD  - New Industry Creation Hatchery Center, Tohoku University, 2-1, Seiryo-machi, 
      Aoba-ku, Sendai, Miyagi 980-8575, Japan.
LA  - eng
PT  - Journal Article
DEP - 20180807
PL  - Netherlands
TA  - Biochem Biophys Rep
JT  - Biochemistry and biophysics reports
JID - 101660999
PMC - PMC6086321
OTO - NOTNLM
OT  - HSC-2
OT  - Monoclonal antibody
OT  - OSCC
OT  - OSCC, oral squamous cell carcinoma
OT  - Oral squamous cell carcinoma
OT  - PODXL
OT  - Podocalyxin
OT  - mAb, monoclonal antibody
EDAT- 2018/08/15 06:00
MHDA- 2018/08/15 06:01
PMCR- 2018/08/07
CRDT- 2018/08/15 06:00
PHST- 2018/07/20 00:00 [received]
PHST- 2018/07/27 00:00 [accepted]
PHST- 2018/08/15 06:00 [entrez]
PHST- 2018/08/15 06:00 [pubmed]
PHST- 2018/08/15 06:01 [medline]
PHST- 2018/08/07 00:00 [pmc-release]
AID - S2405-5808(18)30170-5 [pii]
AID - 10.1016/j.bbrep.2018.07.008 [doi]
PST - epublish
SO  - Biochem Biophys Rep. 2018 Aug 7;15:93-96. doi: 10.1016/j.bbrep.2018.07.008. 
      eCollection 2018 Sep.